Related Experiment Videos

The varicella vaccine. Clinical trials in immunocompromised individuals

A A Gershon1, P LaRussa, S Steinberg

  • 1Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, New York, USA.

Insights

Live attenuated varicella vaccine is safe and effective for immunocompromised children, including those with leukemia in remission. Studies in these high-risk groups enhance understanding of varicella vaccine

Area of Science:

  • Immunology
  • Pediatrics
  • Vaccinology

Background:

  • Immunocompromised children, especially those with leukemia in remission, are at high risk for severe varicella (chickenpox).
  • Understanding the safety and efficacy of live attenuated varicella vaccine in this population is crucial for public health.

Purpose of the Study:

  • To review the safety, immunogenicity, and efficacy of live attenuated varicella vaccine in immunocompromised children.
  • To discuss the unique insights gained from studying varicella vaccine in high-risk pediatric populations.

Main Methods:

  • Literature review of studies on live attenuated varicella vaccine in immunocompromised children.
  • Analysis of data on vaccine safety, immune response, and clinical outcomes.

Main Results:

  • The varicella vaccine demonstrates acceptable safety, immunogenicity, and efficacy in immunocompromised children, including those with leukemia in remission.
  • Studies in this cohort provide valuable information on vaccine virus spread, zoster incidence, and immune correlates.

Conclusions:

  • Live attenuated varicella vaccine is an important tool for protecting high-risk children against severe varicella infections.
  • Research in immunocompromised populations significantly advances our understanding of varicella vaccine dynamics and immune responses.

Related Concept Videos